Moleculin Biotech (MBRX)
(Delayed Data from NSDQ)
$2.36 USD
-0.10 (-4.07%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $2.36 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
F Value B Growth A Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$2.36 USD
-0.10 (-4.07%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $2.36 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
F Value B Growth A Momentum C VGM
Zacks News
Lantheus (LNTH) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Lantheus' (LNTH) fourth-quarter results are likely to reflect solid top-line performance on the back of robust product adoption.
Moleculin (MBRX) Up 7% on Upbeat Updates From Annamycin Studies
by Zacks Equity Research
Moleculin (MBRX) announces positive interim data from its early-mid-stage studies of Annamycin in blood and lung cancer indications, along with encouraging third-quarter results. The stock rises 7%.
Moleculin (MBRX) Posts Update From Lung Cancer Study, Stock Up
by Zacks Equity Research
Moleculin (MBRX) completes enrollment in the phase II portion of the development program for its lead candidate, Annamycin, to treat soft tissue sarcoma lung metastases. The stock rises 10%.
Here's Why Moleculin Biotech, Inc. (MBRX) Looks Ripe for Bottom Fishing
by Zacks Equity Research
Moleculin Biotech, Inc. (MBRX) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
Moleculin Biotech, Inc. (MBRX) Upgraded to Buy: What Does It Mean for the Stock?
by Zacks Equity Research
Moleculin Biotech, Inc. (MBRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Moleculin Surges on Manufacturing Deal for Coronavirus Therapy
by Zacks Equity Research
Moleculin (MBRX) signs an agreement with Sterling Pharma Solutions for manufacturing and supply of WP1122, which is being developed as potential treatment for COVID-19.
Is Moleculin Biotech (MBRX) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (MBRX) Outperforming Other Medical Stocks This Year?
Moleculin Biotech, Inc. (MBRX) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Moleculin Biotech, Inc. (MBRX) closed at $0.96, marking a -0.38% move from the previous day.
Is Moleculin Biotech (MBRX) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (MBRX) Outperforming Other Medical Stocks This Year?
Is Moleculin Biotech (MBRX) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (MBRX) Outperforming Other Medical Stocks This Year?
Seattle Genetics' Adcetris Label Expands in EU for Lymphoma
by Zacks Equity Research
Seattle Genetics (SGEN) secures a nod from the European Commission for Adcetris to treat adult patients with previously untreated systemic anaplastic large cell lymphoma.
Agenus' (AGEN) IND for iNKT Therapy Gets FDA Acceptance
by Zacks Equity Research
The FDA clears Agenus' (AGEN) IND application for allogeneic iNKT therapy, agenT-797, which is being developed to treat cancer as well as the deadly COVID-19 pandemic.
Is Moleculin Biotech (MBRX) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (MBRX) Outperforming Other Medical Stocks This Year?
AMAG Pharmaceuticals (AMAG) Reports Q1 Loss, Beats on Revenues
by Zacks Equity Research
AMAG Pharmaceuticals' (AMAG) loss narrows year over year while sales top estimates in the first quarter of 2020. The company scraps 2020 outlook due to the plaguing pandemic effect.
Moleculin Biotech, Inc. (MBRX) Flat As Market Gains: What You Should Know
by Zacks Equity Research
Moleculin Biotech, Inc. (MBRX) closed the most recent trading day at $1.07, making no change from the previous trading session.
Moleculin Biotech, Inc. (MBRX) Flat As Market Gains: What You Should Know
by Zacks Equity Research
Moleculin Biotech, Inc. (MBRX) closed the most recent trading day at $1.14, making no change from the previous trading session.
Is Moleculin Biotech (MBRX) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (MBRX) Outperforming Other Medical Stocks This Year?
Moleculin (MBRX) Looks Good: Stock Adds 5.3% in Session
by Zacks Equity Research
Moleculin (MBRX) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.
Is Moleculin Biotech (MBRX) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (MBRX) Outperforming Other Medical Stocks This Year?
Moleculin Completes Enrollment in Early-Stage Cancer Study
by Zacks Equity Research
Moleculin (MBRX) reaches enrollment target in a clinical study evaluating its p-STAT3 inhibitor, WP1220, as a treatment for cutaneous T-cell lymphoma, a form of skin cancer.
Moleculin Files New Patents for Cancer Candidate Annamycin
by Zacks Equity Research
Moleculin (MBRX) petitions for new patents to cover annamycin, currently being developed for treating patients with relapsed or refractory acute myeloid leukemia. Shares rise.
Amarin Down on Lower '19 View, Posts Preliminary '18 Results
by Zacks Equity Research
Amarin (AMRN) reports preliminary results for 2018 and issues guidance for 2019. While the results exceeded estimates, outlook missed the same.